The Law Offices of Frank R. Cruz Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz continues its investigation of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On January 5, 2023, after the market closed, Fate announced that it had terminated its collaboration and option agreement for cell-based cancer immunotherapies with Johnson & Johnson’s Janssen, and that all collaboration activities would be wound down in the first quarter of 2023.

On this news, Fate’s stock price fell $6.76, or 61.5%, to close at $4.24 per share on January 6, 2023, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Fate securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles

Frank R. Cruz, 310-914-5007

[email protected]
www.frankcruzlaw.com

Read Previous

Triton Digital Releases the Australian Podcast Ranker for December 2022

Read Next

Topcon Expands Compact Solutions Portfolio with 2D-MC Automatic Grade Control Solution for Compact Track Loaders

Leave a Reply

Most Popular

Please turn AdBlock off